Eureka Therapeutics
Focus: Eureka Therapeutics is a public-stage biotechnology company focused on antibody-based cell therapies, primarily targeting oncology and gastroenterology indications. The company specializes in T-cell engineering and antibody-TCR (AbTCR) platforms with a pipeline concentrated in hematologic and solid tumors.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Eureka Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Eureka Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
17 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT06402266Simultaneous tDCS and Computerised Gamified Short-term Memory Task Feasibility
N/AHelp build intelligence for Eureka Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.